Asco 2022 – great expectations for Adicet, Arcellx and PMV
Unveiled abstracts from Asco lift the stock of several biotechs, which will now be under pressure not to disappoint at the conference next week.
Sanofi moves further into next-gen oncology
Sanofi’s latest acquisition sees the group pay $1bn for the private immuno-oncology company Amunix.
Asco 2021 movers – PDS wins, but big pharma reigns
PDS and Spectrum rise, while Black Diamond, Alpine, Harpoon and Macrogenics disappoint, and others ride on big pharma’s coattails.
US shutdown dampens first-quarter flotations
Biopharma IPOs dipped in the opening months of 2019, but numbers look fairly healthy despite January's US government closure.
After a bumper year, biotech flotations remain on the cards
The buoyant biopharma IPO scene set several new records in 2018, a notable achievement given the stock market turmoil of the fourth quarter.
Pharma news over the Christmas period 2019
If the recent performance of biotech stocks prompted you to pull down the shutters until the New Year celebrations subsided here’s what you might have missed.
